Annual report pursuant to Section 13 and 15(d)

COLLABORATION AND LICENSE AGREEMENTS (Narrative) (Details)

v3.10.0.1
COLLABORATION AND LICENSE AGREEMENTS (Narrative) (Details) - USD ($)
12 Months Ended
Jul. 11, 2018
Jul. 10, 2018
Feb. 02, 2012
Nov. 30, 2018
Nov. 30, 2017
Dec. 31, 2018
Nov. 07, 2018
Jun. 19, 2018
Jan. 31, 2018
Class of Warrant or Right, Grants in Period, Exercise Price       $ 6.24          
Research and Development Expense       $ 6,464,000 $ 2,478,000        
Adva Biotechnology Ltd. [Member]                  
Commitment                 $ 750
Expenses       $ 361,000          
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member]                  
Commitment     $ 15,000            
Royalty of net sales, percentage     3.50%            
Sublicensing fees, percentage     16.00%            
Commitment, shares of common stock     463,651            
Commitment, shares of common stock of subsidiary     1,000            
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase I clinical trials in human subjects [Member]                  
Commitment     $ 50,000            
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase II clinical trials in human subject [Member]                  
Commitment     50,000            
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase III clinical trials in human subjects [Member]                  
Commitment     150,000            
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of issuance of an approval for marketing of the first product by the FDA [Member]                  
Commitment     750,000            
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | When worldwide net sales of Products have reached the amount of $150 million for the first time [Member]                  
Commitment     $ 2,000,000            
Mircod Limited [Member]                  
Collaboration Agreement, royalty percentage               5.00%  
Description of completion of Development Project       Subject to completion of the Development Project, Mircod and the Company are to negotiate and enter into a manufacturing and supply agreement under which Mircod is to manufacture and supply products incorporating the Project Results and, at the Company’s request, to provide support and maintenance service for such products. If for whatever reason the parties fail to enter into such manufacturing and supply agreement within 90 days of the completion of the Development Project or if Mircod is unable to perform such services, the Company is entitled to manufacture the products, in which event Mircod will be entitled to a payment of $80,000 and royalties on Net Sales are to increase to 8% of Net Sales.          
HekaBio K.K [Member]                  
Interest in joint venture   49.00%              
Noncontrolling interest in joint venture   51.00%              
Payments to Acquire Interest in Joint Venture   $ 10,000,000              
Option to affect an equity investment   $ 15,000,000              
Royalty percentage from joint venture   10.00%              
Image Securities Ltd. [Member]                  
Joint venture, equity investment from other partners $ 5,000,000                
Units Issued During Period, Per Unit Amount $ 6.24                
Class of Warrant or Right, Grants in Period, Exercise Price $ 6.24                
Convertible loan advanced to joint venture       $ 1,000,000          
Convertible loan advanced to joint venture, interest rate       6.00%          
Proceeds from Divestiture of Interest in joint venture $ 10,000,000                
Monthly consulting services to joint venture       $ 1,000,000          
Hemogenyx Pharmaceuticals PLC. [Member]                  
Royalty of net sales, percentage       12.00%          
Loans Receivable, Net       $ 500,000   $ 250,000 $ 1,000,000    
Immugenyx, LLC [Member]                  
Royalty of net sales, percentage       12.00%          
Loans Receivable, Net       $ 500,000   $ 250,000 $ 1,000,000    
BG Negev Technologies and Applications (BGN) [Member]                  
Commitment       $ 10,000          
BG Negev Technologies and Applications (BGN) [Member] | Minimum [Member]                  
Royalty of net sales, percentage       2.00%          
Sublicensing fees, percentage       15.00%          
BG Negev Technologies and Applications (BGN) [Member] | Maximum [Member]                  
Royalty of net sales, percentage       4.00%          
Sublicensing fees, percentage       20.00%          
Collaboration agreement [Member]                  
Research and Development Expense       $ 1,200,000          
Service revenue under collaboration agreement       $ 1,000,000